Q-omics provides the consensus-scored TLCD3A profile across patient tissues and cancer cell-line models. TLCD3A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TLCD3A is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TLCD3A RNA expression shows 19,536 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where TLCD3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLCD3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLCD3A survival associations across molecular data types. TLCD3A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLCD3A RNA expression–survival associations across cancer types. High TLCD3A expression shows unfavorable associations in MESO, ACC, KIRP, UVM and KICH, but favorable associations in UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TLCD3A RNA expression.
This table summarizes TLCD3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TLCD3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLCD3A shows higher tumor expression in KIRC, HNSC, COAD, KIRP, LUSC and LIHC. The KIRC box plot shows higher TLCD3A RNA expression in tumor versus normal tissue (log2 FC = +1.944, t-test p < 0.001).
This table shows molecular features associated with TLCD3A in patient tissues and cancer cell lines. In patient samples, TLCD3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TLCD3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
